J. Safra Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

J. Safra Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Sell	297 -61	-17%	-$2.27K	﹤0.01%	391
2026 Q1	$13K	Buy	358 +241	+206%	+$10.8K	﹤0.01%	352
2025 Q4	$5.45K	Buy	117 +21	+22%	+$935	﹤0.01%	410
2025 Q3	$4K	Buy	96 +4	+4%	+$128	﹤0.01%	326
2025 Q2	$2.65K	Buy	92 +20	+28%	+$618	﹤0.01%	339
2025 Q1	$2.42K	Buy	72 +65	+929%	+$2.43K	﹤0.01%	324
2024 Q4	$355	Buy	+7	New	+$392	﹤0.01%	332

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Asset Management's CRNX Position: Q2 2026 in Review

J. Safra Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 17% in Q2 2026, selling an estimated $2.27K and leaving 297 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #391.

J. Safra Asset Management first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $13K in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

J. Safra Asset Management held 297 shares of Crinetics Pharmaceuticals worth $11.1K as of Q2 2026.
J. Safra Asset Management sold 61 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.27K.
Crinetics Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #391 holding.
J. Safra Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
J. Safra Asset Management's Crinetics Pharmaceuticals position peaked at $13K in Q1 2026.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.